Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges - Biogen (NASDAQ:BIIB)

Leqembi, a monoclonal antibody developed by Biogen, has shown promise in slowing cognitive decline in early Alzheimer's patients, such as Missie Meeks, who began treatment in September 2023. Despite its potential benefits, the drug's rollout faces significant logistical hurdles, including diagnostic bottlenecks and insurance complications. Patients must undergo extensive testing, including PET and MRI scans, to determine eligibility, with some clinics requiring genetic testing due to possible side effects like brain swelling. Concerns about the drug's side effects and long-term efficacy have led to caution among some neurologists regarding its prescription. The complexities of managing the treatment's administration have also been highlighted, as many healthcare providers face a steep learning curve. Nevertheless, patients generally feel that the advantages of Leqembi outweigh the associated risks, as evidenced by the growing sales since its approval in July 2023. Biogen reported nearly $60 million in revenue from Leqembi in the first half of 2024, indicating a positive market response. The company is actively working to enhance accessibility by exploring options for simplifying treatment, such as subcutaneous injections and extended infusion intervals. In August, lecanemab became the first treatment targeting the underlying cause of early Alzheimer's to receive authorization in a European country. However, the National Institute for Health and Care Excellence (NICE) has expressed skepticism about the drug's cost-effectiveness, stating that the benefits may not justify the expenses involved. This ongoing debate highlights the challenges faced by new treatments in the healthcare landscape, particularly for conditions like Alzheimer's disease.